Study on the synthesis, physicochemical properties and transdermal absorption of scutellarein prodrugs Authors: Ping Wang, Hong-jian Yu, Zhi-qi Yin, Chang-wei Zhou Published: 2025 ABSTRACT In this research, we aimed to improve the lipid solubility and transdermal absorbability of scutellarein through a prodrug strategy, and then improve its efficacy for treating psoriasis. Firstly, we designed and synthesized 19 prodrugs of scutellarein, including AC (alkylcarbonyl), AAC (alkylaminocarbonyl) and AOC (alkyloxycarbonyl) series. Then, we selected three prodrugs (AC-4, AAC-2 and AOC-SEC-4) with proper log P and favorable solubility for subsequent transdermal absorption study, and the results demonstrated the three prodrugs significantly improved the transdermal flux and the drug retention in the skin. Finally, compared with the parent drug, three prodrugs obviously relieved the dorsal lesions of mice with psoriasis, remarkably reduced the epidermal thickening and Ki67 positive cells. Therefore, this study successfully improved the poor transdermal absorbability of scutellarein, dramatically increased its efficacy in treating psoriasis, and provided candidate compounds for the psoriasis treatment.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-03502-w. Introduction As a common chronic, recurrent and inflammatory skin disease, psoriasis is typically characterized by red papule plaques with silver-white scales attached to the surface and its incidence rate can be up to 0.1%–3% all over the world, of which China is approximately 0.4%, while this data rises to 3% in Europe and America1,2. Current studies suggest the interactions among cells from innate and adaptive immune systems, like keratinocytes (KC cells), T cells, and dendritic cells (DC cells), as well as their related cytokines and chemokines contribute to the occurrence of psoriasis under polygenic inheritance3,4. At present, the therapeutic strategies principally include TNF-antagonists5, IL-12/23 antagonists6 and topical medications for the skin7,8. However, there are still some drawbacks for the above treatments, like the impaired skin barrier function caused by abuse of glucocorticoids9. Therefore, it is of great significance to develop novel candidate drugs with lower toxicity and fewer side effects for long-term psoriasis treatments. TRPV3 (transient receptor potential vanilloid 3) is a type of non-selective cation channel widely expressed in skin keratinocytes as well as in the epithelial cells of oral and nasal cavities10,11. It is reported that TRPV3 expression is significantly increased in psoriatic lesions compared with adjacent non-lesional regions12,13. TRPV3 activation can promote the release of IL-1α from keratinocytes, thereby enhancing the inflammatory response in psoriasis12. Thus, TRPV3 may be a valuable target for psoriasis treatment, and its inhibitors may serve as the candidate drugs or lead molecules . In our previous research, high-throughput screening found scutellarein (SCUE) was a specific TRPV3 inhibitor and a potential therapeutic drug for psoriasis14. As a flavonoid, SCUE is the effective component isolated from Erigeron Breviscapus and Oroxylum indicum both of which possess anti-inflammatory effects15. But its poor solubility and transdermal delivery severely hinder the development of topical formulations. It is reported16 that the water solubility, anticoagulant, and antioxidant activities of scutellarein derivatives are remarkably improved when C-4' hydroxyl group is modified, indicating that C-4' hydroxyl is an optional site for structural modification. In addition, from previous structure–activity relationship results, our group found that the C-4' hydroxyl group was the key site for TRPV3 inhibitory activity, and this position also had excellent reactivity. Prodrugs are biologically inert molecules that undergo enzymatic and/or chemical transformation in vivo to release the pharmacologically active parent drug, thereby increasing bioavailability, solubility, and transdermal absorption capability17,18. Based on prodrug methodology, previous researchers have successfully improved the solubility and transdermal absorbability of certain molecules, such as morphine (an opioid analgesic)19, naltrexone (an opioid antagonist)20–22, and theophylline (a cardiovascular drug)23 by bringing in alkylcarbonyl (AC), alkylaminocarbonyl (AAC) and alkoxycarbonyl (AOC) groups into the respective parent drugs. The above findings suggest that introducing modifying groups at the C-4' hydroxyl position is a meaningful attempt to develop a potentially effective prodrug of SCUE. In this study, we intend to improve the poor solubility and transdermal absorbability of SCUE through a prodrug strategy, thereby improving its efficacy and providing valuable candidate compounds for psoriasis treatment. Results and discussion Chemical synthesis The synthetic route for the 19 prodrugs is shown in Scheme 1. Scutellarin 1 was dissolved in sulfuric acid using an ultrasonic method at room temperature, then the distilled water was added to the above solution drop by drop. Ten minutes later, the above mixture was poured into a large amount of water, then scutellarein 2 was precipitated in the form of yellow solid (yield over 87%)24. For this acid hydrolysis reaction, concentrated sulfuric acid not only function as catalyst, but also provides the heat source needed for acid hydrolysis by releasing heat upon contact with water.Scheme 1Reagents and conditions: (a) H2SO4, H2O, rt, 15 min (b) dichlorodiphenylmethane, Ph2O, 175 ℃, 30 min (c) the corresponding anhydride, dry THF, K2CO3, 70 ℃, 4 h, yield compounds 4–11; the corresponding isocyanate, dry toluene, cat. Et3N, 120 ℃, 2.5 h, yield compounds 12–16; the corresponding chloroformic ester, dry THF, DMAP, rt, 1.5 h, yield compounds 17–22 (d) CF3COOH, rt, 30 min. Reagents and conditions: (a) H2SO4, H2O, rt, 15 min (b) dichlorodiphenylmethane, Ph2O, 175 ℃, 30 min (c) the corresponding anhydride, dry THF, K2CO3, 70 ℃, 4 h, yield compounds 4–11; the corresponding isocyanate, dry toluene, cat. Et3N, 120 ℃, 2.5 h, yield compounds 12–16; the corresponding chloroformic ester, dry THF, DMAP, rt, 1.5 h, yield compounds 17–22 (d) CF3COOH, rt, 30 min. Under nitrogen circumstance, scutellarein 2 was dissolved in diphenyl ether, then reacted with 2.0 equiv. of dichlorodiphenylmethane at 175 ℃ and this reaction produced desired compound 3 in 85% yield after 30 min16. Three series of prodrugs were synthesized as the following 4 methods: (1) Compound 3 was dissolved in anhydrous tetrahydrofuran. And 1.5 equiv. of corresponding anhydrides and anhydrous potassium carbonate were added, respectively. The reaction was performed at 70 ℃ for 4 h under nitrogen circumstance to generate the target compound 4–11. (2) Dry toluene, 1.5 equiv. of corresponding isocyanates and catalytic amount of triethylamine were added to compound 3, respectively. The products 12–16 were synthesized after the reaction was conducted at 120 ℃ for 2.5 h under nitrogen protection. (3) 1.5 equiv. of DMAP was put into compound 3, and then anhydrous tetrahydrofuran was added. The round flask filled with nitrogen was placed at 0 ℃, and 1.5 equiv. of corresponding chloroformates dissolved in dry dichloromethane were added dropwise with the syringe. The reaction was then transferred to room temperature condition for 1.5 h to produce compound 17–22. (4) After products 4–22 were stirred in trifluoroacetic acid solution for 30 min at room temperature, the protective group could be removed and prodrugs 23–41 were finally produced. For the first step of our structural modification route, we refered to the protective methods reported by Shi16, and acquired the desired compound 3 with satisfied yield (> 80%). In the second step of the synthetic route for AC prodrugs, the organic acid with less reactive activity than anhydride was tried to react with compound 3 but no new substances produced. For the de-protection reaction, AcOH/H2O solution with heating reflux was also ultized to remove the protective groups but failed. Then, we tried to remove the protective group in CF3COOH at room temperature, and the protective group turned to be removed within only 15 min with a high yield of over 80%. On one hand, the target aglycone scutellarein (SCUE) was obtained by acid hydrolysis of scutellarin ( the glycoside of SCUE), with purity more than 98% and yield exceeding 87%. On the other hand, the reaction conditions of the structural modification route were mild, with approximately 55% yield. Transdermal absorption evaluation Lipid solubility Compared with scutellarein, the lipid solubility of the prodrugs in IPM was increased by 350 to 4489 times. Thus, the lipid solubility was significantly improved. The detailed results are shown in Table 1.Table 1Linear relationship and solubility of scutellarein and 19 prodrugs.CompoundLinear relationr2Solubility (mg/ml)Linearity range (mg/ml)Increase of lipid solubility1AOC-3y = 2 × 109x-1669050.99920.72314.89 × 10–4 ~ 2.5 × 10–11523.872AOC-ISO-3y = 2 × 109x + 574271.00001.29324.89 × 10–4 ~ 2.5 × 10–12725.383AOC-4y = 2 × 109x-3043950.99990.90844.89 × 10–4 ~ 2.5 × 10–11914.344AOC-ISO-4y = 2 × 109x-5124630.99931.23054.89 × 10–4 ~ 2.5 × 10–12593.225AOC-SEC-4y = 2 × 109x-2366630.99922.13014.89 × 10–4 ~ 2.5 × 10–14489.136AOC-5y = 2 × 109x-2100331.00000.35534.89 × 10–4 ~ 2.5 × 10–1748.827AAC-2y = 2 × 109x-1000000.99900.43954.89 × 10–4 ~ 2.5 × 10–1926.248AAC-3y = 2 × 109x + 149930.99970.16684.89 × 10–4 ~ 2.5 × 10–1351.449AAC-ISO-3y = 2 × 109x-592680.99970.52864.89 × 10–4 ~ 2.5 × 10–11114.1010AAC-4y = 2 × 109x + 7032460.99920.28154.89 × 10–4 ~ 2.5 × 10–1593.3211AAC-6y = 2 × 109x-3569151.00001.16714.89 × 10–4 ~ 2.5 × 10–12459.6712AC-2y = 2 × 109x + 4769510.99920.082704.89 × 10–4 ~ 2.5 × 10–1174.2813AC-3y = 2 × 109x-4158570.99990.26724.89 × 10–4 ~ 2.5 × 10–1563.1514AC-4y = 2 × 109x-2047761.00000.49864.89 × 10–4 ~ 2.5 × 10–11050.8715AC-ISO-4y = 2 × 109x-7565510.99760.64804.89 × 10–4 ~ 2.5 × 10–11365.5416AC-5y = 2 × 109x-2109930.99990.23204.89 × 10–4 ~ 2.5 × 10–1489.0217AC-6y = 2 × 109x-1000000.99930.51394.89 × 10–4 ~ 2.5 × 10–11083.1118AC-7y = 2 × 109x-8268390.99950.55364.89 × 10–4 ~ 2.5 × 10–11166.6819AC-8y = 2 × 109x + 6215890.99880.35094.89 × 10–4 ~ 2.5 × 10–1739.4020SCUEy = 2 × 109x-5373890.99980.00047451.22 × 10–4 ~ 2.5 × 10–1-(1) For the linear relationship, y value is the peak area and x value is the injection mass (mg); (2) The solubility improvement is calculated according to the mass ratio of the prodrug to the scutellarein. Table 1Linear relationship and solubility of scutellarein and 19 prodrugs.CompoundLinear relationr2Solubility (mg/ml)Linearity range (mg/ml)Increase of lipid solubility1AOC-3y = 2 × 109x-1669050.99920.72314.89 × 10–4 ~ 2.5 × 10–11523.872AOC-ISO-3y = 2 × 109x + 574271.00001.29324.89 × 10–4 ~ 2.5 × 10–12725.383AOC-4y = 2 × 109x-3043950.99990.90844.89 × 10–4 ~ 2.5 × 10–11914.344AOC-ISO-4y = 2 × 109x-5124630.99931.23054.89 × 10–4 ~ 2.5 × 10–12593.225AOC-SEC-4y = 2 × 109x-2366630.99922.13014.89 × 10–4 ~ 2.5 × 10–14489.136AOC-5y = 2 × 109x-2100331.00000.35534.89 × 10–4 ~ 2.5 × 10–1748.827AAC-2y = 2 × 109x-1000000.99900.43954.89 × 10–4 ~ 2.5 × 10–1926.248AAC-3y = 2 × 109x + 149930.99970.16684.89 × 10–4 ~ 2.5 × 10–1351.449AAC-ISO-3y = 2 × 109x-592680.99970.52864.89 × 10–4 ~ 2.5 × 10–11114.1010AAC-4y = 2 × 109x + 7032460.99920.28154.89 × 10–4 ~ 2.5 × 10–1593.3211AAC-6y = 2 × 109x-3569151.00001.16714.89 × 10–4 ~ 2.5 × 10–12459.6712AC-2y = 2 × 109x + 4769510.99920.082704.89 × 10–4 ~ 2.5 × 10–1174.2813AC-3y = 2 × 109x-4158570.99990.26724.89 × 10–4 ~ 2.5 × 10–1563.1514AC-4y = 2 × 109x-2047761.00000.49864.89 × 10–4 ~ 2.5 × 10–11050.8715AC-ISO-4y = 2 × 109x-7565510.99760.64804.89 × 10–4 ~ 2.5 × 10–11365.5416AC-5y = 2 × 109x-2109930.99990.23204.89 × 10–4 ~ 2.5 × 10–1489.0217AC-6y = 2 × 109x-1000000.99930.51394.89 × 10–4 ~ 2.5 × 10–11083.1118AC-7y = 2 × 109x-8268390.99950.55364.89 × 10–4 ~ 2.5 × 10–11166.6819AC-8y = 2 × 109x + 6215890.99880.35094.89 × 10–4 ~ 2.5 × 10–1739.4020SCUEy = 2 × 109x-5373890.99980.00047451.22 × 10–4 ~ 2.5 × 10–1-(1) For the linear relationship, y value is the peak area and x value is the injection mass (mg); (2) The solubility improvement is calculated according to the mass ratio of the prodrug to the scutellarein. Linear relationship and solubility of scutellarein and 19 prodrugs. (1) For the linear relationship, y value is the peak area and x value is the injection mass (mg); (2) The solubility improvement is calculated according to the mass ratio of the prodrug to the scutellarein. Lipid-water distribution coefficient (log P) The lipid-water distribution coefficient (log P) of each compound in this study was calculated using Molinspiration software. The results are demonstrated in Table 2. Molecules with a log P between 1 and 3 can easily cross the stratum corneum, which is the skin barrier preventing drug penetration, thereby facilitating effective transdermal absorption25. The log P of scutellarein is only 0.03, while the log P of the AC-4 and AAC-2 are both between 1 and 3, which is benefits transdermal transport of the drugs. Several factors affect the transdermal absorbability, among which logP, solubility and molecular weight are much more influential26. Although the log P of AOC-SEC-4 is not between 1 and 3, its lipid solubility is improved by 4,489 times, which is much higher than the other compounds. Therefore, we selected these three prodrugs for transdermal absorption evaluation.Table 2Lipid–water partition coefficient (log P) of each compound.Compoundlog PMW1AOC-33.47372.082AOC-ISO-33.33372.083AOC-44.03386.14AOC-ISO-43.71386.15AOC-SEC-43.83386.16AOC-54.53400.127AAC-22.44357.088AAC-32.94371.19AAC-ISO-34.53371.110AAC-43.5385.1211AAC-64.51413.1512AC-20.06328.0613AC-30.73342.0714AC-41.29356.0915AC-ISO-43.15356.0916AC-53.97370.1117AC-64.47384.1218AC-74.98398.1419AC-85.48412.1520SCUE0.03286.05 Table 2Lipid–water partition coefficient (log P) of each compound.Compoundlog PMW1AOC-33.47372.082AOC-ISO-33.33372.083AOC-44.03386.14AOC-ISO-43.71386.15AOC-SEC-43.83386.16AOC-54.53400.127AAC-22.44357.088AAC-32.94371.19AAC-ISO-34.53371.110AAC-43.5385.1211AAC-64.51413.1512AC-20.06328.0613AC-30.73342.0714AC-41.29356.0915AC-ISO-43.15356.0916AC-53.97370.1117AC-64.47384.1218AC-74.98398.1419AC-85.48412.1520SCUE0.03286.05 Lipid–water partition coefficient (log P) of each compound. Chemical stability Within 24 h, no degradation of the three prodrugs was observed, and the percentage change of remaining prodrugs was less than 2%, indicating that the prodrug had good chemical stability within 24 h. The percentage of remaining prodrugs is shown in Table 3.Table 3The percentage of remaining prodrugs at different time points (t) (X%).TimeThe percentage of remaining AC-4 (X%)The percentage of remaining AAC-2 (X%)The percentage of remaining AOC-SEC-4 (X%)0 h1001001004 h98.7399.35100.138 h98.48101.0999.2124 h98.87100.9398.56 Table 3The percentage of remaining prodrugs at different time points (t) (X%).TimeThe percentage of remaining AC-4 (X%)The percentage of remaining AAC-2 (X%)The percentage of remaining AOC-SEC-4 (X%)0 h1001001004 h98.7399.35100.138 h98.48101.0999.2124 h98.87100.9398.56 The percentage of remaining prodrugs at different time points (t) (X%). Degradation of prodrugs in skin tissue homogenate Within 24 h, the three prodrugs could be degraded into parent drug by skin esterases. Among them, AOC-SEC-4 and AC-4 were significantly more sensitive than AAC-2. The enzyme sensitivity of AOC-SEC-4 and AC-4 was 7–10 times higher than that of AAC-2. The ratio of the scutellarein peak area to the residual prodrug peak area at different time points (t) is shown in Table 4.Table 4The peak area ratio of scutellarein to residual prodrugs at different time points (t).TimeAreaSCUE:AreaAC-4AreaSCUE:AreaAAC-2AreaSCUE:AreaAOC-SEC-42 h1.07:10.343:10.805:14 h1.36:10.393:10.844:18 h2.16:10.481:12.63:124 h3.50:10.509:14.82:1 Table 4The peak area ratio of scutellarein to residual prodrugs at different time points (t).TimeAreaSCUE:AreaAC-4AreaSCUE:AreaAAC-2AreaSCUE:AreaAOC-SEC-42 h1.07:10.343:10.805:14 h1.36:10.393:10.844:18 h2.16:10.481:12.63:124 h3.50:10.509:14.82:1 The peak area ratio of scutellarein to residual prodrugs at different time points (t). Within 24 h, the ratio of the scutellarein peak area to the residual prodrug peak area in HPLC showed a gradual increase over time, indicating that the prodrug was continuously hydrolyzed to release the active drug, scutellarein. The data are presented in Figs. 1, 2, 3.Fig. 1Peak area ratio of SCUE to residual prodrug AC-4 in HPLC within 24 h.Fig. 2Peak area ratio of SCUE to residual prodrug AAC-2 in HPLC within 24 h.Fig. 3Peak area ratio of SCUE to residual prodrug AOC-SEC-4 in HPLC within 24 h. Peak area ratio of SCUE to residual prodrug AC-4 in HPLC within 24 h. Peak area ratio of SCUE to residual prodrug AAC-2 in HPLC within 24 h. Peak area ratio of SCUE to residual prodrug AOC-SEC-4 in HPLC within 24 h. Transdermal flux Within 24 h, both the parent drug and prodrugs could pass through the skin, but the steady-state flux of scutellarein was significantly lower than that of the prodrugs. The steady-state flux of AOC-SEC-4 was the highest among the three prodrugs, but the difference among the three prodrugs was not obvious. For the residuals in the skin, AC-4 was significantly lower than the other two prodrugs, but the residuals of all three prodrugs inside skin were nearly 2 to 8 times higher than SCUE. The above results are shown in Table 5.Table 5The steady-state flux and the residuals in the skin after 24 h.CompoundSteady-state flux (nmol/cm2/h)Cumulative release amount Q (nmol)Residuals in the skin (nmol/5 ml)2 h4 h8 h24 hAAC-2ntntnt0.61045.97026.255AC-4ntntnt0.64248.3818.16AOC-SEC-4ntntnt0.67250.64221.174SCUEntntntnt02.987nt means not detected at the experimental condition. Table 5The steady-state flux and the residuals in the skin after 24 h.CompoundSteady-state flux (nmol/cm2/h)Cumulative release amount Q (nmol)Residuals in the skin (nmol/5 ml)2 h4 h8 h24 hAAC-2ntntnt0.61045.97026.255AC-4ntntnt0.64248.3818.16AOC-SEC-4ntntnt0.67250.64221.174SCUEntntntnt02.987nt means not detected at the experimental condition. The steady-state flux and the residuals in the skin after 24 h. nt means not detected at the experimental condition. In this transdermal absorption evaluation study, the lipid solubility of scutellarein was increased by 350 to 4,490 times using a prodrug strategy, and its log P was also improved, enhancing its transdermal absorption. Based on the solubility and log P values, three prodrugs (AC-4, AAC-2 and AOC-SEC-4) were selected for the subsequent transdermal flux study. Within 24 h, the three prodrugs showed good chemical stability without hydrolysis. The results of enzyme stability indicated that AOC-SEC-4 and AC-4 were much more sensitive to esterase than AAC-2, and more than 70% of the former two prodrugs could be hydrolyzed to scutellarein after 24 h. The transdermal flux study also revealed that the steady-state flux and residuals in the skin of the three prodrugs were significantly higher than those of SCUE. These results proved the transdermal absorption capacity of scutellarein was significantly improved by the prodrug strategy. The comparison of the treatment for psoriasis between SCUE and prodrugs Preparation of cream In this experiment, the following creams were used: 4.5 g SCUE cream (contain 120 mg SCUE), 4.5 g AC-4 cream (contain 150 mg AC-4), 4.5 g AAC-2 cream (contain 150 mg AAC-2), 4.5 g AOC-SEC-4 cream (contain 162 mg AOC-SEC-4), 4.5 g dexamethasone cream (contain 3.375 mg DXMS) and 8 g vehicle cream. The cream prescription is shown in Table 6.Table 6The cream prescription.Water/oil phaseConstituentQuality/gPrescription analysisWater phaseSCUE/DXMS/AC-4/AAC-2/AOC-SEC-4–Basic remedyTween 804EmulsifierSodium dodecyl sulfate (SDS)0.4EmulsifierGlycerin0.6LubricantEthanol-IPM (1:1)3Penetrant&cosolventPurified water16SolventNipagin ethyl ester0.04PreservativeAzone0.7Penetration enhancerOil phaseGlyceryl monostearate3CoemulsifierPalmitic acid3.6LubricantVaseline2.4Lubricant Table 6The cream prescription.Water/oil phaseConstituentQuality/gPrescription analysisWater phaseSCUE/DXMS/AC-4/AAC-2/AOC-SEC-4–Basic remedyTween 804EmulsifierSodium dodecyl sulfate (SDS)0.4EmulsifierGlycerin0.6LubricantEthanol-IPM (1:1)3Penetrant&cosolventPurified water16SolventNipagin ethyl ester0.04PreservativeAzone0.7Penetration enhancerOil phaseGlyceryl monostearate3CoemulsifierPalmitic acid3.6LubricantVaseline2.4Lubricant The cream prescription. 5% IMQ induced psoriatic lesions in mice 5% IMQ cream was applied to the dorsal skin surface to induce psoriatic lesions. We then removed the lesioned skin and performed histological histological and pathological examinations. It was found that IMQ caused acanthosis thickening, granular layer disappearance and parakeratosis in the skin (Figs. 4A and 5A). Based on the results of the double-blind PASI score, we learnt that continuous application of IMQ cream over several days resulted in psoriatic lesions that progressively worsened over time (Fig. 4B). In addition, H&E staining showed that continuous application of IMQ cream for several days induced significant thickening of the epidermal layer on the back of mice (Fig. 5A,B), and the difference in thickness was statistically significant (P < 0.01). The above results demonstrated that continuous application of 5% IMQ cream could induce psoriatic lesions, which was consistent with the results reported by Luo27.Fig. 4Psoriasis-like lesions on the skin surfaces of mice. (A) Representative images of mice dorsal skins with psoriatic lesions after different drug treatments; (B) The PASI score of mice dorsal psoriatic lesions changed over time. **P < 0.01, vs. Vehicle. ****P < 0.0001, vs. Vehicle. #P < 0.05,vs. SCUE. ##P < 0.01, vs. SCUE. $P < 0.05, vs. IMQ. $$P < 0.01, vs. IMQ.Fig. 5H&E staining of the dorsal skin surfaces of mice. (A) H&E staining of mice dorsal skins after different drug treatments; (B) The epidermal thickness of the dorsal skins of mice after different drug treatments. ####P < 0.001, vs. Vehicle. $$$$P < 0.0001,vs. IMQ. ***P < 0.001, vs. SCUE. ****P < 0.0001, vs. SCUE. Psoriasis-like lesions on the skin surfaces of mice. (A) Representative images of mice dorsal skins with psoriatic lesions after different drug treatments; (B) The PASI score of mice dorsal psoriatic lesions changed over time. **P < 0.01, vs. Vehicle. ****P < 0.0001, vs. Vehicle. #P < 0.05,vs. SCUE. ##P < 0.01, vs. SCUE. $P < 0.05, vs. IMQ. $$P < 0.01, vs. IMQ. H&E staining of the dorsal skin surfaces of mice. (A) H&E staining of mice dorsal skins after different drug treatments; (B) The epidermal thickness of the dorsal skins of mice after different drug treatments. ####P < 0.001, vs. Vehicle. $$$$P < 0.0001,vs. IMQ. ***P < 0.001, vs. SCUE. ****P < 0.0001, vs. SCUE. The prodrug relieved psoriatic lesions induced by 5% IMQ Compared with the model group (IMQ group), both the parent drug group (SCUE group) and the prodrug group (AOC-SEC-4 group, AAC-2 group and AC-4 group) dramatically relieved the skin flushing and thickening (Fig. 4A). The results of skin biopsy and pathological examination also showed that skin acanthosis thickening, as well as the disappearance of granular layer and parakeratosis caused by IMQ cream were greatly relieved after the drug intervention (Fig. 5A). H&E staining showed that three prodrugs obviously reduced the epidermal thickening (P < 0.001). These results indicated that the prodrugs alleviated the psoriatic lesions induced by 5% IMQ, and the efficacy of prodrugs was evidently greater than that of SCUE (P < 0.001). The prodrug reduced Ki67 positive cells in the psoriatic lesions Ki67 is a proliferating cell-associated nuclear antigen whose function is closely related to mitosis and reflects the cell proliferation activity. We used immunofluorescence to label Ki67, and the results (Fig. 6A,B) showed that continuous application of IMQ for several days could enormously increase Ki67 positive cells in the dorsum epidermis (P < 0.0001), while SCUE and prodrugs could reverse the above trend. Besides, a significant difference was observed between AOC-SEC-4 and SCUE in reducing Ki67 positive cells (P < 0.01). Moreover, the efficacy of AOC-SEC-4 was superior to that of DXMS (P < 0.05), while AAC-2 and AC-4 showed efficacy equivalent to DXMS. These results suggested that prodrugs could reduce Ki67-positive cells in psoriatic lesions, indicating that prodrugs were significantly more effective than SCUE in decreasing epidermal keratinocyte overproliferation in psoriatic lesions.Fig. 6Immunofluorescence of mice dorsal skins. (A) Immunofluorescence of mice dorsal skin after different drug treatments; (B) Quantification of keratinocyte proliferation of the dorsal skin of mice after different drug treatments. ****P < 0.0001,vs. Vehicle. #P < 0.05,vs. SCUE. ##P < 0.01.,vs. SCUE. $P < 0.05, vs. IMQ. &P < 0.05, vs. DXMS. Immunofluorescence of mice dorsal skins. (A) Immunofluorescence of mice dorsal skin after different drug treatments; (B) Quantification of keratinocyte proliferation of the dorsal skin of mice after different drug treatments. ****P < 0.0001,vs. Vehicle. #P < 0.05,vs. SCUE. ##P < 0.01.,vs. SCUE. $P < 0.05, vs. IMQ. &P < 0.05, vs. DXMS. Effect of prodrug on spleen weight coefficient Splenomegaly is a characteristic indicator of mouse psoriasis model induced by IMQ. As shown in Fig. 7A,B, obvious splenomegaly was observed in the model group. After treatment with SCUE and prodrugs, the spleen weight coefficient did not decrease notably. However, the positive drug (DXMS) alleviated spleen index, which was nearly the same as the data of blank control group. These results suggested that TRPV3 does not regulate psoriasis by affecting global immunity, whereas DXMS could also regulate global immunity through mechanisms other than TRPV3 channel to alleviate psoriasis. This is consistent with reports by Wang14.Fig. 7Effects of different drugs on spleens in mice. (A) Effects of different drugs on spleen sizes in mice; (B) Effects of different drugs on spleen index in mice. ***P < 0.001, vs. Vehicle. ####P < 0.0001, vs. IMQ. $$$P < 0.001,vs. SCUE. Effects of different drugs on spleens in mice. (A) Effects of different drugs on spleen sizes in mice; (B) Effects of different drugs on spleen index in mice. ***P < 0.001, vs. Vehicle. ####P < 0.0001, vs. IMQ. $$$P < 0.001,vs. SCUE. The above results illuminate that the prodrugs increased the concentration of SCUE in the skin due to the enhanced transdermal absorption capacity, thus further enormously alleviated the epidermal lesions in psoriatic mice, and reduced the epidermal thickening and Ki67 positive cells. This study further confirmed that the efficacy of prodrugs is superior to SCUE, demonstrating their greater therapeutic effect in relieving psoriasis. Conclusion In this research, we designed and synthesized 19 prodrugs including three series, classified into three series: alkyl carbonyl (AC), alkyl aminocarbonyl (AAC), and alkoxycarbonyl (AOC). Based on lipid solubility and log P, three prodrugs (AC-4, AAC-2 and AOC-SEC-4) were selected for subsequent transdermal flux study. The research results demonstrated that both the steady-state fluxes and skin residuals of prodrugs obviously exceeded those of the parent drug. The results for the efficacy showed prodrugs significantly relieved psoriatic lesions on the dorsal skin of mice, also significantly reduced epidermal thickness and decreased the number of Ki67-positive cells. These data indicated the prodrug strategy could improve the therapeutic effect of SCUE on psoriasis. TNF-α can activate the nuclear factor (NF)-κB and thus up-regulate the expression of IL-2328. Psoriasis is also a skin disease affected by the IL-17/IL-23 axis29. Therefore, we plan to further investigate the above inflammatory factors and other related mechanisms to provide more convincing evidence for our research conclusion. Building on prior research30 that optimized fluconazole cream for enhanced antifungal efficacy and reduced side effects, we may also plan to refine our prodrug formulation for improved skin penetration and therapy. Experimental Animal care All animal experiments were approved by the Institutional Animal Care and Use Committee of China Pharmaceutical University (Approval No. SYXK 2016-0011). All procedures were conducted in full accordance with institutional guidelines, the U.K. Animals (Scientific Procedures) Act, 1986, and associated guidelines, EU Directive 2010/63/EU, and the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals (2020). This study is reported in accordance with the ARRIVE guidelines (PLoS Biol 8(6), e1000412, 2010). Efforts were made to reduce the number of animals used and to minimize their suffering. C57BL/6 mice and SD rats were purchased from Qinglongshan Laboratory Animal Center (Nanjing, Jiangsu, China). All the animals were housed in a temperature-controlled (23 ± 2ºC) vivarium under a 12-h light/dark cycle with free access to food and water. When the rats and mice were euthanized, they were placed in a chamber pre-filled with room air. Carbon dioxide (CO2) was then introduced at a gradual displacement rate of 30–70% of the chamber volume every minute, following the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals (2020). This gradual increase in CO2 concentration ensured a humane process, minimizing distress and avoiding involuntary reactions. The animals remained in the chamber until they lost consciousness and exhibited complete respiratory arrest. After cessation of vital signs was confirmed, cervical dislocation was performed as a secondary method to ensure euthanasia was complete before proceeding with subsequent experiments. General methods Scutellarin (1) was obtained from Xi’an Shouhe Biotechnology Co. Ltd. (Xi’an, China). Reagents and solvents were purchased from commercial sources and used without further purification unless otherwise noted. Liquids and solutions sensitive to air or moisture were transferred using a syringe or stainless steel cannula. Organic solutions were concentrated using rotary vacuum film evaporator with no more than 45 ℃ at approximately 20 mm Hg. Nitrogen was blown into the flame-dried reactor filled with freshly distilled organic solvents to ensure the non-aqueous reactions, unless otherwise specified. And all the reactions were monitored by TLC and performed on the 0.15–0.20 mm silica gel plates with UV light detection at a wavelength of 254 nm. Chromatography was performed on silica gel (160–200 mesh) using eluent containing PE/EA or DCM/MeOH. Using Bruker AV-300 (300 MHz) ) or Bruker AV-500 (500 MHz), we obtained the NMR data of every compound (dissolved in DMSO-d6) with their chemical shifts recording in ppm downfield from tetramethylsilane. And peak abbreviations were expressed as follows: s, singlet; d, doublet; m, multiplet. J values were given in Hz. Mass spectra (MS) data were recorded on a Agilent Technologies spectrometer equipped with an electrospray ionization source (ESI). Synthesis of scutellarein prodrugs 7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one (2) To a round-bottomed flask (250 mL) equipped with an efficient magnetic stirrer, scutellarin (1) (5 g, 11 mmol) was first added and then the concentrated sulfuric acid (10.0 mL, 0.185 mmol) was added dropwise. At room temperature, the substrate was dissolved in the acid by ultrasound. Water (10.0 mL) was then added dropwise. Twenty minutes later, the reaction mixture was added to water (500 mL) directly and stirred with a glass rod. After the yellow crystals precipitated, they were collected and washed with a large volume of distilled water. The products were pure enough for next reaction. Moreover, they still could be further purified by recrystallisation from aqueous methanol (80%, v/v) and scutellarein (2) was then gained (2.88 g, 93% yield). 1H NMR (500 MHz, DMSO-d6) δH 10.26 (s, 1H, -OH), 7.92 (d, 2H, J = 9.0 Hz, 2 × Ar–H), 6.92 (d, 2H, J = 8.5 Hz, 2 × Ar–H), 6.72 (s, 1H, -H), 6.58 (s, 1H, Ar–H). 13C NMR (125 MHz, DMSO-d6) δC 182.0, 163.5, 161.0, 153.3, 149.7, 147.1, 129.11, 128.3, 128.3, 121.5, 115.9, 115.9, 104.0, 102.3, 93.8. ESI–MS m/z: [M + H]+ 287.0 (Cal. 287.0). 9-Hydroxy-6-(4-hydroxyphenyl)-2,2-diphenyl-8H-1,3-dioxolo[4,5-g][1] benzopyran-8-one (3) To a round-bottomed flask (1000 mL) containing diphenyl ether (300 mL), scutellarein (2) (10 g, 34.94 mmol) and dichlorodiphenylmethane (12.4 g, 52.29 mmol, 1.5 equiv) were added and then the inner air was replaced by nitrogen. The reaction mixture was heated at 175 ℃ for 30 min with an oil bath pan equipped with an efficient magnetic stirrer, which was then allowed to cool to room temperature. Afterwards, the reaction mixture was directly poured into the petroleum ether (1000 mL). The yellow solid deposited was filtered, and then purified by column chromatography (PE:EA = 3:1) and finally compound 3 was obtained (13.35 g, 85% yield). Synthesis of 4–11 To the reactor (250 mL) containing anhydrous potassium carbonate (1.0 g, 7.25 mmol), compound 3 (3.0 g, 6.67 mmol) dissolved in anhydrous tetrahydrofuran (100 mL) and anhydride (10.0 mmol) were added, then the reaction was conducted at 70 ℃ for 4 h under nitrogen . After the reaction ceased, the solvent was drained in the vacuum environment, and the products 4–11 obtained could be directly used for the next step. Synthesis of 12–16 Compound 3 (3.0 g, 6.67 mmol) was added to the reactor (250 mL) containing dried toluene, and the inner air was replaced by nitrogen. Afterwards, isocyanate (10.0 mmol) and the catalytic amount of triethylamine were added to the mixture and then the reaction was carried out at 125 ℃ for 2.5 h and then allowed to cool. Finally, compounds 12–16 were acquired. Synthesis of 17–22 Compound 3 (3.0 g, 6.67 mmol) and DMAP (1.6 g, 13 mmol) were added to the round bottom flask (500 mL) containing anhydrous tetrahydrofuran (200 mL). The reactor was placed in a cold trap at 0 ℃ under nitrogen. Then the chloroformate (0.85 ~ 1.05 g, 7.0 mmol) dissolved in anhydrous dichloromethane (30 mL) was added dropwise to the reactor with stirring and the temperature range was less than 5 ℃. Afterwards, the reaction temperature was increased to room temperature and the reaction was carried out for 1.5 h to afford compounds 17–22. Synthesis of 23–41 Compounds 4–22 (3.5 g) and trifluoroacetic acid (130 mL) were added to the reactor (500 mL), and the reaction was then carried out for 1 h at room temperature. Afterwards, ethyl acetate (150 mL) was added to the reaction mixture and then the mixture was extracted with brine three times. The organic layer was collected, dried over Na2SO4, filtered, concentrated, and evaporated under the reduced pressure. The crude products could be purified by column chromatography (PE:EA = 3:1) to afford compounds 23–41. 4-(5,6,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl acetate (23, AC-2). Light yellow solid, 81% yield. 1H NMR (500 MHz, DMSO-d6) δH 12.83 (s, 1H, -OH), 10.72 (s, 1H, -OH), 8.95 (s, 1H, -OH), 8.30 (d, 2H, J = 8.5 Hz, 2 × Ar–H), 7.53 (d, 2H, J = 8.5 Hz,2 × Ar–H), 7.10 (s, 1H, -CH), 6.81 (s, 1H, Ar–H), 2.70 (s, 3H, -CH3). 13C NMR (125 MHz, DMSO-d6) δC 182.0, 171.3, 162.2, 153.6, 153.1, 149.8, 147.0, 129.3, 128.5, 127.8, 122.5, 104.5, 104.2, 94.0, 35.3, 17.7, 13.3. HR-ESI m/z: [M + Na]+ 351.04779 (Cal. 351.04752). 4-(5,6,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl propionate (24, AC-3). Light yellow solid, 84% yield. 1H NMR (300 MHz, DMSO-d6) δH 12.65 (s, 1H, -OH), 10.60 (s, 1H, -OH), 8.83 (s, 1H, -OH), 8.12 (d, 2H, J = 8.5 Hz, 2 × Ar–H), 7.34 (d, 2H, J = 8.5 Hz, 2 × Ar–H), 6.93 (s, 1H, -CH), 6.63 (s, 1H, Ar–H), 2.67 (m, 2H, -CH2), 1.15 (t, 3H, J = 5.7 Hz, -CH3). 13C NMR (125 MHz, DMSO-d6) δC 182.1, 172.2, 162.2, 153.6, 153.1, 149.8, 147.0, 129.3, 128.4, 127.8, 122.5, 104.4, 104.2, 94.0, 26.9, 8.7. HR-ESI m/z: [M + Na]+ 365.06377 (Cal. 365.06317). 4-(5,6,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl butyrate (25, AC-4). Light yellow solid, 85% yield.. 1H NMR (300 MHz, DMSO-d6) δH 12.66 (s, 1H, -OH), 10.59 (s, 1H, -OH), 8.83 (s, 1H, -OH), 8.12 (d, 2H, J = 8.5 Hz, 2 × Ar–H), 7.33 (d, 2H, J = 8.5 Hz, 2 × Ar–H), 6.93 (s, 1H, -CH), 6.63(s, 1H, Ar–H), 2.60 (t, 2H, J = 5.4 Hz, -CH2), 1.68 (m, 2H, -CH2), 0.97 (t, 3H, J = 5.4 Hz, -CH3). 13C NMR (125 MHz, DMSO-d6) δC 182.0, 168.9, 162.2, 153.6, 153.1, 149.8, 147.0, 129.3, 128.5, 127.8, 122.6, 104.5, 104.2, 94.0, 20.8. HR-ESI m/z: [M + H]+ 357.09661 (Cal. 357.09688). 4-(5,6,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl isobutyrate (26, AC-ISO-4). Light yellow solid, 83% yield. 1H NMR (300 MHz, DMSO-d6) δH 12.65 (s, 1H, -OH), 10.59 (s, 1H, -OH), 8.83 (s, 1H, -OH), 8.13 (d, 2H, J = 8.5 Hz, 2 × Ar–H), 7.33 (d, 2H, J = 8.5 Hz, 2 × Ar–H), 6.94 (s, 1H, -CH), 6.63 (s, 1H, Ar–H), 2.85 (m, 1H, -CH), 1.26 (d, 6H, J = 5.4 Hz, 2 × -CH3). 13C NMR (125 MHz, DMSO-d6) δC 182.0, 174.7, 162.2, 153.6, 153.2 149.8, 147.0, 129.3, 128.5, 127.8, 122.5, 104.5, 104.2, 94.0, 33.3, 18.5. HR-ESI m/z: [M + Na]+ 379.07853 (Cal. 379.07882). 4-(5,6,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl pentanoate (27, AC-5). Light yellow solid, 87% yield. 1H NMR (500 MHz, DMSO-d6) δH 12.52 (s, 1H, -OH), 10.41 (s, 1H, -OH), 8.65 (s, 1H, -OH), 8.00 (d, 2H, J = 10.0 Hz, 2 × Ar–H), 7.20 (d, 2H, J = 8.5 Hz, 2 × Ar–H), 6.80 (s, 1H, -H), 6.51 (s, 1H, Ar–H), 2.52 (t, 2H, -CH2), 1.53 (m, 2H, -CH2), 1.29 (m, 2H, -CH2), 0.81 (t, 3H, J = 7.5 Hz, -CH3). 13C NMR (125 MHz, DMSO-d6) δC 182.0, 171.5, 162.2, 153.6, 153.1, 149.8, 147.0, 129.3, 128.5, 127.8, 122.5, 104.5, 104.2, 94.0, 33.2, 26.3, 21.5, 13.5. HR-ESI m/z: [M + H]+ 371.11154 (Cal. 371.11253). 4-(5,6,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl hexanoate (28, AC-6). Light yellow solid, 84% yield. 1H NMR (500 MHz, DMSO-d6) δH 12.53 (s, 1H, -OH), 10.42 (s, 1H, -OH), 8.66 (s, 1H, -OH), 8.01 (d, 2H, J = 10.0 Hz, 2 × Ar–H), 7.22 (d, 2H, J = 8.5 Hz, 2 × Ar–H), 6.81 (s, 1H, -CH), 6.52 (s, 1H, Ar–H), 2.52 (t, 2H, -CH2), 1.57 (m, 2H, -CH2), 1.27 (m, 4H, 2 × -CH2), 0.79 (t, 3H, J = 7.0 Hz, -CH3). 13C NMR (125 MHz, DMSO-d6) δC 182.0, 171.5, 162.2, 153.6, 153.0, 149.8, 147.0, 129.3, 128.5, 127.8, 122.5, 104.5, 104.2, 93.97, 33.4, 30.5, 23.9, 21.7, 13.7. HR-ESI m/z: [M—H]− 383.11558 (Cal. 383.11308). 4-(5,6,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl heptanoate (29, AC-7). Light yellow solid, 83% yield. 1H NMR (300 MHz, DMSO-d6) δH 12.65 (s, 1H, -OH), 8.11 (d, 2H, J = 8.5 Hz, 2 × Ar–H), 7.32 (d, 2H, J = 8.5 Hz, 2 × Ar–H), 6.92 (s, 1H, -CH), 6.62 (s, 1H, Ar–H), 2.59 (t, 2H, -CH2), 1.63 (m, 2H, -CH2), 1.34 ~ 1.22 (m, 6H,3 × -CH2), 0.86 (t, 3H, J = 5.1 Hz, -CH3). 13C NMR (125 MHz, DMSO-d6) δC 182.0, 171.5, 162.2, 153.6, 153.1, 149.8, 147.0, 129.3, 128.5, 127.8, 122.5, 104.4, 104.2, 94.0, 33.4, 30.8, 28.0, 24.2, 21.9, 13.8. HR-ESI m/z: [M—H]- 397.13112 (Cal. 397.12873). 4-(5,6,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl octanoate (30, AC-8). Light yellow solid, 84% yield. 1H NMR (500 MHz, DMSO-d6) δH 12.53 (s, 1H, -OH), 10.43 (s, 1H, -OH), 8.66 (s, 1H, -OH), 8.01 (d, 2H, J = 10.0 Hz, 2 × Ar–H), 7.22 (d, 2H, J = 10.0 Hz, 2 × Ar–H), 6.81 (s, 1H, -CH), 6.52 (s, 1H, Ar–H), 2.40 (t, 2H, -CH2), 1.55 (m, 2H, -CH2), 1.28 ~ 1.15 (m, 8H, 4 × -CH2), 0.77 (t, 3H, J = 6.0 Hz, -CH3). 13C NMR (125 MHz, DMSO-d6) δC 182.0, 171.5, 162.2, 153.6, 153.1, 149.8, 147.0, 129.3, 128.5, 127.8, 122.5, 104.4, 104.2, 94.0, 33.4, 31.0, 28.3, 28.3, 24.2, 22.0, 13.8. HR-ESI m/z: [M—H]− 411.14689 (Cal. 411.14438). 4-(5,6,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl ethylcarbamate (31, AAC-2). Light yellow solid, 87% yield. 1H NMR (500 MHz, DMSO-d6) δH 12.66 (s, 1H, -OH), 10.51 (s, 1H, -OH), 8.75 (s, 1H, -OH), 8.07 (d, 2H, J = 9.0 Hz, 2 × Ar–H), 7.86 (t, 1H, J = 5.5 Hz, -NH), 7.29 (d, 2H, J = 8.5 Hz, 2 × Ar–H), 6.89 (s, 1H, -CH), 6.62 (s, 1H, Ar–H), 3.12 (m, 2H, -CH2), 1.10 (t, 3H, J = 7.5 Hz, -CH3). 13C NMR (125 MHz, DMSO-d6) δC 182.0, 162.9, 162.4, 153.9, 153.6, 153.5, 149.8, 147.0, 129.3, 127.6, 127.4, 122.2, 104.2, 94.0, 35.3, 14.7. HR-ESI m/z: [M—H]− 356.07920 (Cal. 356.07700). 4-(5,6,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl propylcarbamate (32, AAC-3). Light yellow solid, 84% yield. 1H NMR (500 MHz, DMSO-d6) δH 12.66 (s, 1H, -OH), 8.07 (d, 2H, J = 9.0 Hz, 2 × Ar–H), 7.88 (t, 1H, J = 5.5 Hz, -NH), 7.31 (d, 2H, J = 9 Hz, 2 × Ar–H), 6.89 (s, 1H, -CO–CH = C), 6.62 (s, 1H, Ar–H), 3.06 (m, 2H, -CH2), 1.51 (m, 2H, -CH2), 0.90 (t, 3H, J = 7.5 Hz, -CH3). 13C NMR (125 MHz, DMSO-d6) δC 182.0, 162.9, 162.4, 153.9, 153.7, 153.6, 149.8, 147.0, 129.3, 127.6, 127.4, 122.1, 104.2, 94.0, 42.3, 22.4, 11.2. HR-ESI m/z: [M—H]− 370.09471 (Cal. 370.09268). 4-(5,6,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl isopropylcarbamate (33, AAC-ISO-3). Light yellow solid, 81% yield. 1H NMR (500 MHz, DMSO-d6) δH 12.66 (s, 1H, -OH), 10.51 (s, 1H, -OH), 8.75 (s, 1H, -OH), 8.07 (d, 2H, J = 8.5 Hz, 2 × Ar–H), 7.82 (d, 1H, J = 8.0 Hz, -NH), 7.31 (d, 2H, J = 8.5 Hz, 2 × Ar–H), 6.89 (s, 1H, -CH), 6.62 (s, 1H, Ar–H), 3.71 ~ 3.62 (m, 1H, -CH), 1.15 (d, 6H, J = 6.5 Hz, 2 × -CH3). 13C NMR (125 MHz, DMSO-d6) δC 182.0, 162.9, 162.4, 153.9, 153.6, 152.7, 149.8, 147.0, 129.3, 127.6, 127.4, 122.1, 104.2, 94.0, 42.8, 22.3. HR-ESI m/z: [M—H]− 370.09438 (Cal. 370.09268). 4-(5,6,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl butylcarbamate (34, AAC-4). Light yellow solid, 84% yield. 1H NMR (500 MHz, DMSO-d6) δH 12.66 (s, 1H, -OH), 10.51 (s, 1H, -OH), 8.75 (s, 1H, -OH), 8.07 (d, 2H, J = 9.0 Hz, 2 × Ar–H), 7.86 (t, 1H, J = 6.0 Hz, -NH), 7.30 (d, 2H, J = 9.0 Hz, 2 × Ar–H), 6.89 (s, 1H, -CH), 6.62 (s, 1H, Ar–H), 3.11 ~ 3.07 (m, 2H, -CH2), 1.50 ~ 1.44 (m, 2H, -CH2), 1.37 ~ 1.30 (m, 2H, -CH2), 0.90 (t, 3H, J = 7.5 Hz, -CH3). 13C NMR (125 MHz, DMSO-d6) δC 182.0, 162.9, 162.4, 153.9, 153.6, 153.6, 149.8, 147.0, 129.3, 127.6, 127.4 122.1, 104.2, 94.0, 40.1, 31.2, 19.4, 13.6. HR-ESI m/z: [M + H]+ 386.12468 (Cal. 386.12343). 4-(5,6,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl hexylcarbamate (35, AAC-6). Light yellow solid, 82% yield. 1H NMR (500 MHz, DMSO-d6) δH 12.66 (s, 1H, -OH), 10.51 (s, 1H, -OH), 8.75 (s, 1H, -OH), 8.07 (d, 2H, J = 8.5 Hz, 2 × Ar–H), 7.86 (t, 1H, J = 6.0 Hz, -NH), 7.30 (d, 2H, J = 9.0 Hz, 2 × Ar–H), 6.89 (s, 1H, -CH), 6.62 (s, 1H, Ar–H), 3.10 ~ 3.03 (m, 2H, -CH2), 1.51 ~ 1.43 (m, 2H, -CH2), 1.34 ~ 1.23 (m, 6H, 3 × -CH2), 0.88 (t, 3H, J = 6.0 Hz, -CH3). 13C NMR (125 MHz, DMSO-d6) δC 182.0, 162.9, 162.4, 153.9, 153.6, 153.6, 149.77, 147.0 129.3, 127.6, 127.4, 122.1, 104.2, 94.0, 40.5, 30.9, 29.0, 25.8, 22.0, 13.8. HR-ESI m/z: [M—H]− 412.14192 (Cal. 412.13963). Propyl (4-(5,6,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl) carbonate (36, AOC-3). Light yellow solid, 82% yield. 1H NMR (300 MHz, DMSO-d6) δH 12.64 (s, 1H, -OH), 8.15 (d, 2H, J = 9.0 Hz, 2 × Ar–H), 7.45 (d, 2H, J = 9.0 Hz, 2 × Ar–H), 6.97 (s, 1H, -CH), 6.63 (s, 1H, Ar–H), 4.19 (t, 2H, J = 6.6 Hz, -CH2), 1.67 (m, 2H, -CH2), 0.94 (t, 3H, J = 7.5 Hz, -CH3). 13C NMR (125 MHz, DMSO-d6) δC 182.0, 162.0, 153.6, 153.1, 152.5, 149.8, 147.0, 129.3, 128.8, 127.9, 122.0, 104.6, 104.2, 94.0, 70.2, 21.4, 10.0. HR-ESI m/z: [M—H]− 371.07867 (Cal. 371.07669). Isopropyl (4-(5,6,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl) carbonate (37, AOC-ISO-3). Light yellow solid, 85% yield. 1H NMR (500 MHz, DMSO-d6) δH 12.63 (s, 1H, -OH), 10.54 (s, 1H, -OH), 8.77 (s, 1H, -OH), 8.14 (d, 2H, J = 8.5 Hz, 2 × Ar–H), 7.45(d, 2H, J = 8.5 Hz, 2 × Ar–H), 6.93 (s, 1H, -CH), 6.63 (s, 1H, Ar–H), 4.93 (m, 1H, -CH), 1.34 (d, 6H, J = 6.5 Hz, 2 × -CH3). 13C NMR (125 MHz, DMSO-d6) δC 182.0, 162.1, 153.6, 153.1, 151.9, 149.8, 147.0, 129.3, 128.7, 127.9, 122.0, 104.6, 104.2, 94.0, 73.3, 21.3. HR-ESI m/z: [M—H]− 371.07861 (Cal. 371.07669). Butyl (4-(5,6,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl) carbonate (38, AOC-4). Light yellow solid, 83% yield. 1H NMR (500 MHz, DMSO-d6) δH 12.63 (s, 1H, -OH), 10.53 (s, 1H, -OH), 8.77 (s, 1H, -OH), 8.13 (d, 2H, J = 9.0 Hz, 2 × Ar–H), 7.45 (d, 2H, J = 9.0 Hz, 2 × Ar–H), 6.93 (s, 1H, -CH), 6.63 (s, 1H, Ar–H), 4.24 (t, 2H, J = 6.5 Hz, -CH2), 1.67 (m, 2H, -CH2), 1.40 (m, 2H, -CH2), 0.93 (t, 3H, J = 7.5 Hz, -CH3). 13C NMR (125 MHz, DMSO-d6) δC 182.0, 162.0, 153.6, 153.1, 152.5, 149.8, 147.0, 129.3, 128.8, 127.9, 122.0, 104.6, 104.2, 94.0, 68.5, 30.0, 18.3, 13.4. HR-ESI m/z: [M + Na]+ 409.09046 (Cal. 409.08939). Isobutyl (4-(5,6,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl) carbonate (39, AOC-ISO-4). Light yellow solid, 88% yield. 1H NMR (500 MHz, DMSO-d6) δH 12.61 (s, 1H, -OH), 10.59 (s, 1H, -OH), 8.78 (s, 1H, -OH), 8.13 (d, 2H, J = 8.5 Hz, 2 × Ar–H), 7.46(d, 2H, J = 8.5 Hz, 2 × Ar–H), 6.93 (s, 1H, -CH), 6.65 (s, 1H, Ar–H), 4.41 (d, 1H, J = 6.5 Hz, -CH), 2.00 (m, 1H, -CH), 0.96 (d, 6H, J = 7.0 Hz, 2 × -CH3). 13C NMR (125 MHz, DMSO-d6) δC 182.0, 162.0, 153.6, 153.1, 152.6, 149.8, 147.0, 129.3, 128.8, 127.9, 122.0, 104.6, 104.2, 94.0, 74.4, 27.2, 18.6. HR-ESI m/z: [M—H]− 385.09470 (Cal. 385.09234). Sec-butyl (4-(5,6,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl) carbonate (40, AOC-SEC-4). Light yellow solid, 84% yield. 1H NMR (500 MHz, DMSO-d6) δH 12.63 (s, 1H, -OH), 10.54 (s, 1H, -OH), 8.77 (s, 1H, -OH), 8.12 (d, 2H, J = 9.0 Hz, 2 × Ar–H), 7.45 (d, 2H, J = 9.0 Hz, 2 × Ar–H), 6.93 (s, 1H, -CH), 6.63 (s, 1H, Ar–H), 4.76 (m, 1H, -CH), 1.66 (m, 2H, -CH2), 1.31 (d, 3H, J = 6.5 Hz, -CH3), 0.92 (t, 3H, J = 7.5 Hz, -CH3). 13C NMR (125 MHz, DMSO-d6) δC 182.0, 162.0, 153.6, 153.2, 152.1, 149.8, 147.0, 129.3, 128.7, 127.9, 122.0, 104.6, 104.2, 94.0, 77.7, 28.0, 18.9, 9.2. HR-ESI m/z: [M + Na]+ 409.08979 (Cal. 409.08939). Pentyl (4-(5,6,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl) carbonate (41, AOC-5). Light yellow solid, 81% yield. 1H NMR (500 MHz, DMSO-d6) δH 12.62 (s, 1H, -OH), 10.53 (s, 1H, -OH), 8.77 (s, 1H, -OH), 8.13 (d, 2H, J = 8.5 Hz, 2 × Ar–H), 7.45 (d, 2H, J = 9.0 Hz, 2 × Ar–H), 6.93 (s, 1H, -CH), 6.63 (s, 1H, Ar–H), 4.23 (t, 2H, J = 7.0 Hz, -CH2), 1.69 (m, 2H, -CH2), 1.34 (m, 4H, 2 × -CH2), 0.89 (t, 3H, J = 7.0 Hz, -CH3). 13C NMR (125 MHz, DMSO-d6) δC 182.0, 162.0, 153.6, 153.1, 152.5, 149.8, 147.0, 129.3, 128.8, 127.9, 122.0, 104.6, 104.2, 94.0, 68.8, 27.6, 27.2, 21.6, 13.7. HR-ESI m/z: [M—H]− 399.11057 (Cal. 399.10799). Study on physicochemical properties and transdermal absorption The establishment of a standard curve Dissolve 4.00 mg of the compound (purity ≥ 98%) in a 2.0 mL volumetric flask with methanol (containing 10% tetrahydrofuran) to prepare a 2.00 mg/mL solution. Then, transfer 1 mL of this solution into another clean 2.0 mL volumetric flask and dilute to 2.0 mL with methanol (containing 10% tetrahydrofuran) to prepare a 1.00 mg/mL solution. Repeat the above procedure sequentially to obtain solutions with concentrations of 0.25, 0.0625, 0.01563, 0.001953, and 0.000489 mg/mL. Filter each solution through a 0.45 μm membrane filter before analysis by HPLC. Determination of lipid solubility Approximately 0.5 mL of IPM was placed into an EP tube, and 2 mg of the tested compound was added. At 25 ℃, the EP tube containing the tested compound was placed in an ultrasonic cleaning machine for 30 min. Due to the saturated state of the compound in the solvent, partial compounds could not continue to be dissolved and were suspended or precipitated in the EP tube, and then suspension was filtered with 0.45 μm filter membrane. The filtrate was then analyzed to measure solubility by HPLC. The calculation of lipo-hydro partition coefficient (log P ) The lipo-hydro partition coefficient (log P) of each compound was calculated using the Molinspiration software platform. Chemical stability measurement 1.5 mg of the compound was dissolved in 8 mL of PBS buffer solution containing 10% ethanol at 32 ℃, and then the solution was stirred with a magnetic stirrer for 24 h. Afterwards, 1.5 mL of the solution was taken out at 0 h, 4 h, 8 h and 24 h and then measured by HPLC to get the prodrug residual percentage (X%). Preparation of rats skins The abdominal skin of SD rats was smeared with depilating cream to remove the abdominal hair, and then the rats were fed for 24 h. The rats were euthanized and the abdominal skin was removed surgically. The subcutaneous tissue and fat were carefully removed, and the skin was rinsed with normal saline. Preparation of skin tissue homogenate The above skins (20 g) were minced and put into a 100 mL centrifuge tube and 60 mL PBS (pH = 7.4) was added . The mixture was homogenized for 15 min in ice bath, and then centrifuged at 4 ℃ for 15 min at 6000 rpm. The supernatant was taken out and placed at − 20 ℃ for subsequent use. The mixture was homogenized for 15 min in an ice bath, and then centrifuged at 4 ℃ for 15 min at 6000 rpm. The supernatant was collected and stored at − 20 ℃ for subsequent use. Degradation measurement of prodrug in skin tissue homogenate 1 mL of anhydrous ethanol was added to 4 mL skin tissue homogenate supernatant. At 32 ℃, an appropriate amount of the prodrug was dissolved in the prepared solution. Aliquots of 1 mL were taken at 2, 4, 8 and 24 h. The ratio of the scutellarein peak area to the residual prodrug peak area (X%) was determined by HPLC. A function describing the relationship between the peak area ratio (X%) and time (t) was established. Transdermal absorption measurement Four drugs were tested: scutellarein, AOC-SEC-4, AAC-2 and AC-4. The skin fragments were thawed immediately prior to use. The skin samples were mounted onto the diffusion cells with the stratum corneum side facing up. The donor compartment was filled with an IPM-ethanol (1:1,V/V) solution containing the prodrug or parent drug at a 2% molar concentration. The receptor compartment (approximately 18 mL) of the diffusion cell was filled with PBS (pH 7.4) containing 10% ethanol. The precise volume of the receptor solution was measured for each diffusion cell. The Franz diffusion cells were maintained at 32 °C in a water bath and stirred at 250 rpm. Samples (3 mL) were collected from the receptor compartment at 2, 4, 8, and 24 h. At the same time, an equal volume of fresh receptor solution was added. The collected samples were stored at − 20 °C for subsequent HPLC analysis. Measurement of drug retention in skin The concentration of prodrugs and the parent drug retained in the skin was measured after 24 h. The skin tissue was washed with distilled water. This method could remove the residual parent drug and prodrugs from the skin surface, but did not affect the internal parent drug or prodrugs. The tissue was weighed, then cut into small pieces and placed into a centrifuge tube containing methanol. The tissue-to-solvent ratio was 100 mg:1 mL. The mixture was homogenized for 15 min in an ice bath, then centrifuged at 4 ℃ for 15 min at 6000 rpm. The supernatant was collected and analyzed by HPLC. In vivo efficacy test Preparation of cream Prodrugs or the parent drug were added to the aqueous phase, which contained Tween 80 (4 g), sodium dodecyl sulfate (0.4 g), glycerol (0.6 g), ethanol (1.5 g), isopropyl myristate (1.5 g), purified water (16 g), ethylparaben (0.04 g), and Azone (0.7 g). The mixture was then stirred until the prodrugs or parent drug were completely dissolved. The oil phase, containing glycerol monostearate (3 g), palmitic acid (3.6 g), and white petrolatum (2.4 g), was heated in a water bath at 80 °C until dissolved. Then, the aqueous phase was slowly added to the oil phase while stirring until the mixture reached a semi-solid state. Finally, the cream was obtained. Immunofluorescence staining of paraffin sections The paraffin sections were put into the oven (60℃) for 20 min, and then were put into Xylene I, Xylene II, 95% Ethanol, 85% Ethanol and 75% Ethanol in turn, and finally were washed with distilled water and PBS. The sections were then placed in antigenic repair buffer with 5% BSA and sealed at room temperature for 1 h. After that, the sections were placed at 4 ℃ and incubated overnight. The next day, a fluorescent secondary antibody was added to the sections, then the sections were incubated at room temperature for 1 h in the dark, and followed by dropping Hoechst (diluted at the ratio of 1:1000), incubated at room temperature in the dark for 15 min, and finally sealed with anti-fluorescence quenching sealing tablets. The psoriasis model induced by imiquimod(IMQ) The modeling method was designed according to Shi31. After removing the back hair of mice, 62.5 mg 5% IMQ cream was smeared on the back of mice for modeling every day, and modeling period was 6 days in total. The control group was given equal quality of Vaseline. The severity of the psoriasis model was evaluated by Psoriasis Area and Severity Index (PASI). The PASI scoring criteria and corresponding symptoms were as follows: 0 = no symptoms, 1 = mild, 2 = moderate, 3 = severe, 4 = extremely severe. Preparation of paraffin sections After mice were euthanized, dorsal skin samples were carefully excised and immediately fixed in 10% neutral buffered formalin for 24 h. Fixed tissues were then dehydrated through a graded ethanol series (70%, 80%, 90%, 95%, and 100%), cleared in xylene, and embedded in paraffin wax. Tissue blocks were sectioned at a thickness of 4 μm, using a microtome, and the sections were mounted on glass slides for subsequent staining procedures. H&E staining After dewaxing, paraffin sections were placed in hematoxylin dye for 5 min, and rinsed with distilled water. The sections were then placed in a hydrochloric acid/ethanol solution, differentiated for 30 s, soaked in distilled water for 15 min, and then placed in eosin dye for 2 min. Finally, the sections were mounted with neutral resin. Determination of spleen weight coefficient After the final administration, the mice were fasted overnight (water was provided ad libitum). The body weight of each mouse was recorded prior to sacrifice. Mice were euthanized following standard animal welfare guidelines, as described in Sect. 4.1 Animal care. Immediately after euthanasia, the spleens were carefully harvested, blotted with filter paper to remove surface moisture, and weighed using an electronic balance. The spleen weight coefficient was calculated using the following formula:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\hbox{Spleen weight coefficient} = \frac{{\text{Spleen weight (mg)}}}{{\text{Body weight (g)}}}$$\end{document} Statistical analysis The severity of lesions in IMQ-induced psoriasis models was quantified based on the modified PASI scoring criteria31. The quantitative data obtained in the experiment were expressed as mean ± SD., and presented in the form of a histogram. Statistical analysis was performed with GraphPad Prism 6.0 software (Graph Pad Software Inc, CA, USA), and all results were expressed in the form of mean ± SD. A t test was utilized for comparisons between two groups, and one-way analysis of variance (ANOVA) was performed for comparisons among multiple groups. Differences with P < 0.05 were considered statistically significant. HPLC system and conditions High-performance liquid chromatography (HPLC) was performed using a Waters HPLC system equipped with a 2998 photodiode array (PDA) detector and a Waters-Pack ODS column (250 × 20 mm, 5 μm; Waters Technologies, USA). The mobile phase consisted of methanol and 0.1% trifluoroacetic acid in water, with specific ratios for each compound provided in the Supplementary Material. Isocratic elution was employed at a flow rate of 1.0 mL/min. The detection wavelength was set at 335 nm. The column temperature was maintained at 30 °C, and the injection volume was 10 μL. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2 Supplementary Material 3 Supplementary Material 3